Clinical Trials Browser

Breast Neoplasms × GSK2141795 × Clear all

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

37 enrolled 17 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00920257 2017-11-13

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Phase 1 Completed

BreastGynecologicLymphoid

Breast Neoplasms, Lymphoma, Neoplasms, Endometrial Neoplasms